Curis Inc
NASDAQ:CRIS
Intrinsic Value
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. [ Read More ]
The intrinsic value of one CRIS stock under the Base Case scenario is 9.33 USD. Compared to the current market price of 15.22 USD, Curis Inc is Overvalued by 39%.
Valuation Backtest
Curis Inc
Run backtest to discover the historical profit from buying and selling CRIS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Curis Inc
Current Assets | 60.9m |
Cash & Short-Term Investments | 56.3m |
Receivables | 2.8m |
Other Current Assets | 1.8m |
Non-Current Assets | 16.4m |
PP&E | 3.5m |
Intangibles | 9m |
Other Non-Current Assets | 3.9m |
Current Liabilities | 13.5m |
Accounts Payable | 3.2m |
Accrued Liabilities | 10.3m |
Non-Current Liabilities | 44.1m |
Other Non-Current Liabilities | 44.1m |
Earnings Waterfall
Curis Inc
Revenue
|
10m
USD
|
Cost of Revenue
|
-212k
USD
|
Gross Profit
|
9.8m
USD
|
Operating Expenses
|
-58.1m
USD
|
Operating Income
|
-48.3m
USD
|
Other Expenses
|
919k
USD
|
Net Income
|
-47.4m
USD
|
Free Cash Flow Analysis
Curis Inc
What is Free Cash Flow?
CRIS Profitability Score
Profitability Due Diligence
Curis Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Curis Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
CRIS Solvency Score
Solvency Due Diligence
Curis Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
Curis Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRIS Price Targets Summary
Curis Inc
According to Wall Street analysts, the average 1-year price target for CRIS is 22.19 USD with a low forecast of 15.15 USD and a high forecast of 27.3 USD.
Ownership
CRIS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CRIS Price
Curis Inc
Average Annual Return | 65.66% |
Standard Deviation of Annual Returns | 218.35% |
Max Drawdown | -100% |
Market Capitalization | 89.7m USD |
Shares Outstanding | 5 894 080 |
Percentage of Shares Shorted | 0.85% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.
Contact
IPO
Employees
Officers
The intrinsic value of one CRIS stock under the Base Case scenario is 9.33 USD.
Compared to the current market price of 15.22 USD, Curis Inc is Overvalued by 39%.